Connect with us
Byron Bay News and Weather copy
Mt Warning News and Weather copy
Kyogle News
Grafton News and Events copy
Byron Bay News and Weather copy
Mt Warning News and Weather copy
Kyogle News
Grafton News and Events copy
previous arrow
next arrow

Health News

Towards a New Drug Class in the Treatment of Type 2 Diabetes

Published

on

Advertisements
MadeComfy

Towards a New Drug Class in the Treatment of Type 2 Diabetes 

Type 2 diabetes is a major public health problem that affects millions of people worldwide. Developing new drugs to help better treat its underlying causes is therefore a research priority.

In a new study coordinated by Inserm researcher Vincent Marion in collaboration with Monash University, the University of Birmingham (UK), and Alexander Fleming, former senior endocrinologist at the US Food and Drug Administration (FDA), the scientists have developed PATAS, a peptide that is part of a new class of antidiabetic drugs. PATAS can correct the metabolic abnormalities leading to type 2 diabetes and its associated comorbidities which include insulin resistance(1).

PATAS works by specifically targeting the adipocytes (fat cells) (2), restoring glucose entry and thus correcting and re-establishing the metabolic physiology of the adipose tissue. The teams hope to set up a clinical trial soon to test this new therapy. Their study has been published in the journal Diabetes.

Diabetes mellitus is a chronic condition that affects 537 million people worldwide, with the majority affected by type 2 diabetes. The prevalence of type 2 diabetes, which is characterized by high levels of glucose in the blood (see box), has been increasing for decades due to population aging, inactivity, and poor diet. The age of onset is also decreasing, and although the disease is considered to be an “adult disease”, it is now seen frequently in adolescents and children.

Available drugs treat the consequences of type 2 diabetes by focusing mainly on lowering blood glucose; they do not target the underlying biological mechanism that causes the disease. Despite the urgency for developing new and more effective treatments, there have been no disruptive therapeutic innovations to reach market in over a decade.

And this is precisely the objective of the research led by Inserm researcher Vincent Marion and his team at the Medical Genetics Laboratory (Inserm/Université de Strasbourg). In a recent study in collaboration with the University of Birmingham and Monash University, the scientists have developed a product called PATAS in a new class of diabetes drugs called “Adipeutics” (for therapies that specifically target the adipocytes).

Their study, conducted on animal models, shows that this new therapy specifically restores glucose uptake in the adipocytes, resulting in the treatment of insulin resistance with beneficial effects on the whole body. This is made all the more promising by the fact that treating insulin resistance has the potential to address not only type 2 diabetes but a large array of serious medical conditions that result from this resistance.

 

Type 2 diabetes in brief 

Diabetes mellitus is characterized by excessive blood glucose levels over a prolonged period of time: this is known as hyperglycemia.

Hyperglycemia is caused by a reduced sensitivity of the cells, particularly those in the liver, muscle, and adipose tissue, to insulin. This is known as “insulin resistance.”

Insulin is a hormone produced by the pancreas whose role is to facilitate the entry of glucose into the body cells as their main source of energy.  To meet the increased demand for insulin caused by the cells’ resistance to this hormone, the pancreas produces even more insulin, depleting the body requirements. Insulin production then becomes insufficient and the blood glucose levels rise as a result.

The role of adipocytes 

This study follows on from years of rigorous, in depth work carried out in the lab. In previous research, published in Diabetes in 2020, the scientists had identified a new therapeutic target for type 2 diabetes when investigating at an ultra-rare monogenic disease known as Alström syndrome.

The scientists had shown that adipose tissue abnormalities (3) caused by a dysfunctional protein called ALMS1 led to extremely severe insulin resistance associated with early-onset type 2 diabetes in people with Alström syndrome. In animal models, restoring the function of this protein within the adipocytes re-established blood glucose balance.

The teams then went on to focus more closely on ALMS1 and how it interacts with other proteins within the adipocytes. In particular, they have shown that in the absence of insulin, ALMS1 binds to another protein called PKC alpha. The activation of insulin in the adipocytes induces the separation of these two proteins ALMS1 and PKC alpha, resulting in glucose entry into cells. In people with diabetes, who are insulin-resistant, this link between the two proteins is maintained.

Drawing on this knowledge, the scientists have developed the peptide PATAS, which works by breaking the interaction between ALMS1 and PKC alpha – thus restoring insulin signaling in the adipocytes.

In mouse models of diabetes, PATAS has been able to re-establish the normal physiology of the adipocytes by restoring glucose uptake. “Thanks to PATAS, the adipocytes that could no longer access glucose were once again able to absorb it and then metabolize it in order to synthesize and secrete lipids which are beneficial to the entire body. These positive effects are visible in our animal models, with a marked improvement in insulin resistance. Other parameters and comorbidities are also improved, including better blood glucose control and decreased liver fibrosis and steatosis,” explains Vincent Marion.

These promising results in animals have paved the way for the researchers to organise a clinical trial as soon as possible, in order to test PATAS in humans. The successful development of a new class of antidiabetic drugs could have significant implications for public health, not only to treat type 2 diabetes but also many other cardio-metabolic disorders in which dysfunctional adipocytes and insulin resistance are very problematic.

In order to create value from these findings and facilitate the organization of such a trial, Vincent Marion has founded the start-up AdipoPharma SAS.

 

Advertisements
Tenterfield-The Bowlo
Continue Reading

Health News

Northern Rivers health workers up for awards

Published

on

By

Advertisements
MadeComfy

Northern Rivers health workers up for awards

By Tim Howard

Staff from Northern NSW Local Health District have been named as finalists for the 2024 NSW Health Awards for their extraordinary efforts to improve the NSW public health system.

Now in its 26th year, the awards acknowledge the personalised, sustainable, and digitally enabled programs that contribute to the wellbeing of patients and the community.

The Rheumatic Heart Disease Project and the Rural Paediatric Complex Care Coordination Project are among 42 finalists from across the state competing for the Excellence in Aboriginal Healthcare Award and Health Innovation Award, respectively.

The Rheumatic Heart Disease Project  aims to address the significant public health issue of Acute Rheumatic Fever (ARF) and RHD among Aboriginal communities in Northern NSW.

The project was led by Aboriginal Health Nurse Manager Emma-Jane Davies and supported by Robin Auld, Sally Adams and Daniel Ashton, with valuable advice and advocacy from Aboriginal Medical Service partners, in particular Scott Monaghan from Bulgarr Ngaru Medical Aboriginal Corporation.

The Rural Paediatric Complex Care Coordination Project improves care coordination for regional NSW children, reduces family costs and disruptions, and improves outcomes for families in regional NSW.

This is a joint project with Northern NSW, Murrumbidgee, Southern NSW and Western NSW local health districts, together with the Sydney Children’s Hospitals Network.

Rheumatic Heart Disease Project team members, from left, Tracy Bradshaw (Aboriginal Health Worker, Chronic Care for Aboriginal People), Sasha Harrington (Aboriginal Health Engagement and Governance Manage), Daniel Ashton (Aboriginal Health Performance and Project Analyst), Emma-Jane Davies (Nurse Manager Aboriginal Health) and Kirsty Glanville (executive director Aboriginal Health, NNSWLHD).

Northern NSW Local Health District also partnered with Justice Health, the Forensic Mental Health Network, NSW Health Pathology and NSW Health in the NSW Dried Blood Spot Validation Study that has been named a finalist in the Health Innovation Award.

This project is the first of its kind, and aims to make dried blood spot testing a standard diagnostic tool and, if successful, will change how testing is offered for people at risk of hepatitis C.

NNSWLHD chief executive Tracey Maisey praised the achievements of local finalists who have been recognised for their passion and commitment.

“I am thrilled to congratulate our NNSWLHD staff on having their outstanding contributions to our health system recognised,” Ms Maisey said.

NSW Health secretary Susan Pearce AM said it is really exciting to celebrate the people and teams who are enriching health in millions of ways every day.

“These awards are a chance to recognise our incredible healthcare staff and volunteers, across the public health system,” Ms Pearce said.

“I congratulate the finalists, but I also want to acknowledge the work being done across the system every day, by our teams of doctors, nurses, midwives, allied health and support staff.”

NSW Health received 186 nominations across the 12 award categories.

The finalists and winners will be celebrated at the NSW Health Awards ceremony, which will be held on Thursday, October 24 at the International Convention Centre in Sydney.

It will also be livestreamed from 6pm.

Advertisements
Tenterfield-The Bowlo
Continue Reading

Health News

Forty per cent of women from Northern NSW overdue for breast screening

Published

on

By

Advertisements
MadeComfy

Forty per cent of women from Northern NSW overdue for breast screening

By Ian Rogers

This Breast Cancer Awareness Month, women aged 50-74 in the Northern NSW Local Health District are being encouraged to schedule a free mammogram, as over 40% (44.7%) of women in the region are overdue for their biannual breast cancer screening.

Patrick Magee, Acting Director of BreastScreen NSW’s North Coast Screening and Assessment Service, emphasized that with around 300 local women expected to be diagnosed with breast cancer this year, now is the time to book a free, potentially life-saving breast screen.

“For women aged 50-74, a breast screen every two years is still the best way to detect breast cancer early – before it can be seen or felt,” Mr Magee said.

“If you’re aged 50 – 74, make breast screening a priority. It only takes 20 minutes and no doctor’s referral is needed.”

This Breast Cancer Awareness Month, BreastScreen NSW is urging women to “Be A Friend, Tell A Friend” about the importance of regular mammograms. The campaign encourages women to spread the word through conversation and social media, reminding friends, family, and colleagues to prioritize breast cancer screenings.

Professor Tracey O’Brien AM, NSW Chief Cancer Officer and CEO of the Cancer Institute NSW, highlighted that early detection is key: when breast cancer is found in its earliest stages, the five-year survival rate is 98 percent. However, this drops to 43.9 percent when the cancer has spread to other organs.

“More than 6500 women in NSW are expected to receive a breast cancer diagnosis this year, and 1,000 women are expected to lose their lives to the disease in 2024, so we need to do everything we can to support women and encourage them to book in a life-saving breast screen,” Professor O’Brien said.

“Early detection not only significantly increases a person’s chance of survival it can also greatly reduce the need for invasive treatment like a mastectomy.

“I know how hard it can be to block out time for yourself. Unfortunately, breast cancer doesn’t wait, so I encourage all eligible women to stop and put themselves first – for themselves and their family.”

Breast cancer is the most common cancer among women, with age and gender being the biggest risk factors—family history is not the primary concern.

Women aged 50-74 are advised to have a breast screen every two years. BreastScreen NSW also recommends that Aboriginal women begin screening at 40, as research indicates they are more likely to be diagnosed at a younger age, with more advanced cancer at diagnosis and poorer survival rates compared to the general female population.

Any woman who notices changes in her breasts, such as a lump, should consult her doctor immediately.

For more information and to make an appointment at a local BreastScreen NSW clinic or mobile van, call 13 20 50 or book online at www.breastscreen.nsw.gov.au.

For more information about the Be A Friend Tell A Friend promotion visit here.

Advertisements
Tenterfield-The Bowlo
Continue Reading

Health News

Breast Cancer Awareness Month

Published

on

By

NSW-Northern-Rivers-Breaking-News
Advertisements
MadeComfy

Breast Cancer Awareness Month

The Honorable Aileen MacDonald has reminded the public that October is Breast Cancer Awareness Month.

Ms. MacDonald emphasised the importance of supporting the National Breast Cancer Foundation during this time, as breast cancer remains the second most commonly diagnosed cancer in Australia, claiming the lives of nine people each day.

“The aim of Breast Cancer Awareness Month is to shine a light on the devastating impact breast cancer has on thousands of Australians each day,” Ms MacDonald said.

“The statistics are alarming. Every year more than 21,000 people in Australia, including around 200 men, will be diagnosed with breast cancer,” she said.

“It saddens me that every year more than 3,300 people in Australia, including 33 men, will die from breast cancer.”

Ms. MacDonald encouraged everyone to undergo screenings, as early detection significantly improves the chances of successful treatment for breast cancer confined to the breast.

“If you experience any symptoms such as lumps, dimples, discharge or discolouration, head to your doctor for further examination,” she said.

For further information Ms MacDonald said visit the National Breast Cancer Foundation website.

Advertisements
Tenterfield-The Bowlo
Continue Reading

NRTimes Online

ADVERTISEMENT

National News Australia

Facebook

Latest News

Verified by MonsterInsights